Back

Genistein effect on cognition in early Alzheimer's disease patients. The GENIAL clinical trial

2022-06-02 geriatric medicine Title + abstract only
View on medRxiv
Show abstract

BackgroundDelaying the transition from minimal cognitive impairment to Alzheimers dementia is a major concern in Alzheimers disease (AD) therapeutics. Pathological signs of AD occur years before the onset of clinical dementia. Thus, long-term therapeutic approaches, with safe, minimally invasive, and yet effective substances are recommended. There is a need to develop new drugs to delay Alzheimers dementia. We have taken a nutritional supplement approach with genistein, a chemically defined pol...

Predicted journal destinations